Base to Base Biotech
Base to Base Biotech
Podcast Description
The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world.Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.
Podcast Insights
Content Themes
The podcast covers a range of topics within the biotech realm, including new drug developments, technological advancements, clinical trial results, and product launches. Specific episodes highlight innovations like non-addictive pain alternatives and wearable devices for bone health, alongside discussions on artificial intelligence in disease diagnostics and cancer immunotherapy strategies. Each episode aims to keep listeners informed and engaged with the dynamic biotech sector.
The Base to Base Biotech podcast is a weekly look at what’s happening in the world of biotech, with interviews with biotech leaders around the world.
Whether it’s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.
The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.
Base to Base is an Ayr Coastal Media Ltd production.
This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics.
Times:
03:34 Purespring
24:11 Panakeia Technologies
Purespring Therapeutics
Purespring is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.
The company is focused on transforming the treatment of kidney disease—an area of enormous unmet need, with more than 840m people worldwide living with chronic kidney disease.
Purespring’s lead programme, PS-002, for IgA nephropathy (IgAN) is set to enter the clinic this quarter. It marks the first podocyte-targeted gene therapy to reach clinical development and offers a highly differentiated approach compared with other emerging treatments, including those from Vertex and Otsuka.
Panakeia Technologies
Panakeia Technologies recently published a real-world clinical validation showing that AI can determine critical colorectal cancer biomarkers in minutes, in a test across 1,243 patients and 3,576 images in NHS hospitals.
While not yet used directly in patient care, the study demonstrates the potential for AI to support clinical decision-making, reduce lab bottlenecks, and help clinicians act faster — a topic highly relevant to the goals of the UK government’s cancer plan and the ongoing discussion around innovation in healthcare.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.